Parameningeal rhabdomyosarcoma in pediatric age: results of a pooled analysis from North American and European cooperative groups
- PMID: 24356633
- PMCID: PMC3868324
- DOI: 10.1093/annonc/mdt426
Parameningeal rhabdomyosarcoma in pediatric age: results of a pooled analysis from North American and European cooperative groups
Erratum in
- Ann Oncol. 2014 Mar;25(3):756
-
Parameningeal rhabdomyosarcoma in pediatric age: results of a pooled analysis from North American and European cooperative groups.Ann Oncol. 2014 Mar;25(3):756. doi: 10.1093/annonc/mdu001. Epub 2019 Dec 4. Ann Oncol. 2014. PMID: 32664045 Free PMC article. No abstract available.
Abstract
Background: Parameningeal (PM) site is a well-known adverse prognostic factor in children with localized rhabdomyosarcoma (RMS). To identify risk factors associated with outcome at this site, we pooled data from 1105 patients treated in 10 studies conducted by European and North American cooperative groups between 1984 and 2004.
Patients and methods: Clinical factors including age, histology, size, invasiveness, nodal involvement, Intergroup Rhabdomyosarcoma Study (IRS) clinical group, site, risk factors for meningeal involvement (MI), study group, and application of radiotherapy (RT) were studied for their impact on event-free and overall survival (EFS and OS).
Results: Ten-year EFS and OS were 62.6 and 66.1% for the whole group. Patients without initial RT showed worse survival (10-year OS 40.8% versus 68.5% for RT treated patients). Multivariate analysis focusing on 862 patients who received RT as part of their initial treatment revealed four unfavorable prognostic factors: age <3 or >10 years, signs of MI, unfavorable site, and tumor size. Utilizing these prognostic factors, patients could be classified into different risk groups with 10-year OS ranging between 51.1 and 80.9%.
Conclusions: While, in general, PM localization is regarded as an adverse prognostic factor, the current analysis differentiates those with good prognosis (36% patients with 0-1 risk factor: 10-year OS 80.9%) from high-risk PM patients (28% with 3-4 factors: 10-year OS 51.1%). Furthermore, this analysis reinforces the necessity for RT in PM RMS.
Keywords: meningeal involvement; parameningeal; radiotherapy; rhabdomyosarcoma.
Figures
Similar articles
-
Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study Group trials II through IV.Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):1027-38. doi: 10.1016/j.ijrobp.2004.02.064. Int J Radiat Oncol Biol Phys. 2004. PMID: 15234036
-
[Clinical and prognostic analysis of single-center multidisciplinary treatment for rhabdomyosarcoma in children].Zhonghua Er Ke Za Zhi. 2019 Oct 2;57(10):767-773. doi: 10.3760/cma.j.issn.0578-1310.2019.10.008. Zhonghua Er Ke Za Zhi. 2019. PMID: 31594063 Chinese.
-
European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors.J Clin Oncol. 2004 Dec 1;22(23):4787-94. doi: 10.1200/JCO.2004.04.083. J Clin Oncol. 2004. PMID: 15570080
-
Prognostic factors and surgical treatment guidelines for children with rhabdomyosarcoma of the perineum or anus: a report of Intergroup Rhabdomyosarcoma Studies I through IV, 1972 through 1997.J Pediatr Surg. 2003 Mar;38(3):347-53. doi: 10.1053/jpsu.2003.50106. J Pediatr Surg. 2003. PMID: 12632347 Review.
-
Outcome and Patterns of Relapse in Childhood Parameningeal Rhabdomyosarcoma Treated With Proton Beam Therapy.Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):1043-1054. doi: 10.1016/j.ijrobp.2019.08.005. Epub 2019 Aug 13. Int J Radiat Oncol Biol Phys. 2019. PMID: 31419513 Review.
Cited by
-
Clinicopathological Features and Prognostic Factors of Sinonasal Rhabdomyosarcoma.In Vivo. 2022 Nov-Dec;36(6):2965-2972. doi: 10.21873/invivo.13040. In Vivo. 2022. PMID: 36309350 Free PMC article.
-
Patterns of Hearing Loss in Irradiated Survivors of Head and Neck Rhabdomyosarcoma.Cancers (Basel). 2022 Nov 23;14(23):5749. doi: 10.3390/cancers14235749. Cancers (Basel). 2022. PMID: 36497230 Free PMC article.
-
A snotty nose: more than just a cold.BMJ Case Rep. 2018 Oct 12;2018:bcr2018226686. doi: 10.1136/bcr-2018-226686. BMJ Case Rep. 2018. PMID: 30317210 Free PMC article. No abstract available.
-
Radiation therapy is an important factor to improve survival in pediatric patients with head and neck rhabdomyosarcoma by enhancing local control: a historical cohort study from a single center.BMC Pediatr. 2020 May 29;20(1):265. doi: 10.1186/s12887-020-02165-y. BMC Pediatr. 2020. PMID: 32471472 Free PMC article.
-
Excessive Treatment Failures in Patients With Parameningeal Rhabdomyosarcoma With Reduced-dose Cyclophosphamide and Delayed Radiotherapy.J Pediatr Hematol Oncol. 2018 Jul;40(5):387-390. doi: 10.1097/MPH.0000000000001188. J Pediatr Hematol Oncol. 2018. PMID: 29683960 Free PMC article.
References
-
- Miller RW, Young JL, Jr, Novakovic B. Childhood cancer. Cancer. 1995;75:395–405. - PubMed
-
- Arndt CA, Stoner JA, Hawkins DS, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children's Oncology Group study D9803. J Clin Oncol. 2009;27:5182–5188. - PMC - PubMed
-
- Dantonello TM, Int-Veen C, Harms D, et al. Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. J Clin Oncol. 2009;27:1446–1455. - PubMed
-
- Oberlin O, Rey A, Sanchez de Toledo J, et al. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study. J Clin Oncol. 2012;30:2457–2465. - PubMed
-
- Raney RB, Meza J, Anderson JR, et al. Treatment of children and adolescents with localized parameningeal sarcoma: experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978–1997. Med Pediatr Oncol. 2002;38:22–32. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases